Explore more topics
News sentiment

Dermata Therapeutics, Inc. Common Stock (DRMA) news sentiment

How positive or negative Dermata Therapeutics, Inc. Common Stock's news headlines have been since Aug 9, 2021, week by week, with the last 90 sessions day by day and each recent headline's tone and source.

As of 2026-11-06

Average tone, last 30 sessions
+99From -100 (every headline negative) to +100 (every headline positive)
Headlines, last 30 sessions
7
Headlines, last 90 sessions
39
Change from the 90-session average
+63
Latest session
2026-11-06

Weekly headline tone since August 2021

Hover a week for its biggest stories; click to pin.

Tone8-week averageHeadlines
Every week since Aug 9, 2021
DRMA headline tone: Every week since Aug 9, 2021, 111 weeks from August 9, 2021 to October 26, 2026.-100-75-50-25+25+50+75+1000Headlines20222023202420252026

Coverage of Dermata Therapeutics, Inc. Common Stock over the last 30 trading sessions is positive (+99) across 7 headlines, 70 points above its one-year average of +29. The most widely carried story in the week of Oct 26, 2026 was "Dermata Therapeutics: Dermata Advances Second Tome Skincare Product Toward Expected 2027 Launch with Initiation of Acne Clinical Trial", carried by 1 outlet.

Each point is one week of headlines about Dermata Therapeutics, Inc. Common Stock: the share of positive minus negative headlines, from -100 to +100, with the 8-week average drawn through it and the number of headlines beneath. Since coverage began, 271 headlines average +24.

Jump to a section

Tone mix

DRMA headlines by tone, last 52 weeks
positive
33%
neutral
64%
negative
3%

Week by week 52 weeks

Jun 17, 2024: 0 positive, 1 neutral, 0 negativeJul 1, 2024: 0 positive, 1 neutral, 0 negativeJul 15, 2024: 1 positive, 1 neutral, 0 negativeJul 22, 2024: 2 positive, 0 neutral, 0 negativeJul 29, 2024: 0 positive, 3 neutral, 0 negativeAug 5, 2024: 0 positive, 2 neutral, 1 negativeAug 12, 2024: 0 positive, 0 neutral, 1 negativeSep 2, 2024: 0 positive, 3 neutral, 0 negativeSep 16, 2024: 3 positive, 3 neutral, 1 negativeSep 30, 2024: 0 positive, 2 neutral, 0 negativeOct 7, 2024: 0 positive, 3 neutral, 0 negativeNov 11, 2024: 0 positive, 6 neutral, 0 negativeDec 2, 2024: 1 positive, 0 neutral, 0 negativeDec 9, 2024: 1 positive, 0 neutral, 0 negativeJan 20, 2025: 4 positive, 3 neutral, 0 negativeJan 27, 2025: 1 positive, 1 neutral, 0 negativeMar 10, 2025: 0 positive, 1 neutral, 0 negativeMar 17, 2025: 0 positive, 1 neutral, 0 negativeMar 24, 2025: 6 positive, 2 neutral, 0 negativeMar 31, 2025: 1 positive, 1 neutral, 0 negativeApr 14, 2025: 1 positive, 2 neutral, 0 negativeMay 12, 2025: 0 positive, 1 neutral, 0 negativeJun 9, 2025: 0 positive, 1 neutral, 0 negativeAug 11, 2025: 0 positive, 2 neutral, 0 negativeSep 8, 2025: 2 positive, 0 neutral, 0 negativeSep 15, 2025: 0 positive, 5 neutral, 0 negativeNov 17, 2025: 0 positive, 1 neutral, 0 negativeDec 8, 2025: 1 positive, 0 neutral, 0 negativeDec 22, 2025: 1 positive, 4 neutral, 0 negativeDec 29, 2025: 3 positive, 1 neutral, 0 negativeJan 12, 2026: 0 positive, 1 neutral, 0 negativeJan 19, 2026: 1 positive, 0 neutral, 0 negativeFeb 23, 2026: 0 positive, 1 neutral, 0 negativeMar 2, 2026: 0 positive, 1 neutral, 0 negativeMar 9, 2026: 0 positive, 1 neutral, 0 negativeMar 16, 2026: 0 positive, 1 neutral, 0 negativeMar 23, 2026: 1 positive, 2 neutral, 0 negativeMar 30, 2026: 2 positive, 2 neutral, 0 negativeApr 6, 2026: 0 positive, 1 neutral, 0 negativeMay 11, 2026: 0 positive, 2 neutral, 0 negativeMay 18, 2026: 1 positive, 0 neutral, 0 negativeMay 25, 2026: 0 positive, 2 neutral, 0 negativeJul 13, 2026: 0 positive, 1 neutral, 0 negativeJul 27, 2026: 0 positive, 2 neutral, 0 negativeAug 3, 2026: 3 positive, 0 neutral, 0 negativeAug 10, 2026: 1 positive, 6 neutral, 1 negativeAug 17, 2026: 1 positive, 6 neutral, 0 negativeAug 24, 2026: 3 positive, 4 neutral, 0 negativeAug 31, 2026: 0 positive, 3 neutral, 0 negativeSep 7, 2026: 0 positive, 1 neutral, 0 negativeOct 12, 2026: 4 positive, 0 neutral, 0 negativeOct 26, 2026: 1 positive, 0 neutral, 0 negative
Jun 17, 2024Oct 26, 2026

Share of Dermata Therapeutics, Inc. Common Stock's 138 headlines over the last 52 weeks by the model's call, and the same mix week by week.

Biggest swings in the last year

The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.

Daily headline tone, last 90 sessions

Hover a session for its totals; click to pin.

Session tone8-session averageHeadlines
Last 25 sessions with a headline
DRMA average headline tone by session: Last 25 sessions with a headline, 25 sessions from July 14, 2026 to November 6, 2026.-100-75-50-25+25+50+75+1000HeadlinesJul 2026AugSepOctNov

Each point is the average score of the headlines about Dermata Therapeutics, Inc. Common Stock in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.

Tone by period

Show the table · 3 rows, 3 columns

Scroll sideways to compare all columns. Select a heading to sort.

Last 7 sessions3+98
Last 30 sessions7+99
Last 90 sessions39+36

Every headline in the period counts equally.

Headlines on Friday, November 6, 2026

1 headline, average tone +95: 1 positive, 0 neutral and 0 negative. Showing all 1.

Show the table · 1 row, 4 columns

Scroll sideways to compare all columns. Select a heading to sort.

Dermata Therapeutics Highlights Media Recognition of Tome Skincare ...www.pr-inside.com1Positive

Headlines on Thursday, November 5, 2026

1 headline, average tone +99: 1 positive, 0 neutral and 0 negative. Showing all 1.

Show the table · 1 row, 4 columns

Scroll sideways to compare all columns. Select a heading to sort.

Dermata Therapeutics Highlights Media Recognition of Tome Skincare Following Commercial Launchwww.finanznachrichten.de2Positive

Headlines on Friday, October 30, 2026

1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.

Show the table · 1 row, 4 columns

Scroll sideways to compare all columns. Select a heading to sort.

Dermata Therapeutics: Dermata Advances Second Tome Skincare Product Toward Expected 2027 Launch with Initiation of Acne Clinical Trialwww.finanznachrichten.de1Positive

Headlines on Friday, October 16, 2026

2 headlines, average tone +100: 2 positive, 0 neutral and 0 negative. Showing all 2.

Show the table · 2 rows, 4 columns

Scroll sideways to compare all columns. Select a heading to sort.

Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatmentwww.californiatelegraph.com2Positive
Skin in the Game for Dermata Therapeutics, Inc. (NASDAQ:DRMA) Big Gains on Positive Topline Results from Cosmetic Studywww.investorideas.com1Positive

Headlines on Thursday, October 15, 2026

2 headlines, average tone +100: 2 positive, 0 neutral and 0 negative. Showing all 2.

Show the table · 2 rows, 4 columns

Scroll sideways to compare all columns. Select a heading to sort.

Dermata Therapeutics Announces Positive Topline Results from Cosmetic ...www.pr-inside.com1Positive
Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatmentwww.finanznachrichten.de1Positive

How the score works

A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.

  1. Which headlines count

    Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Dermata Therapeutics, Inc. Common Stock, not a passing mention.

  2. How each headline is scored

    The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).

  3. When a headline counts

    Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.

  4. Repeated stories

    When several outlets carry the same headline, it counts once per session.